<?xml version='1.0' encoding='utf-8'?>
<document id="18258455"><sentence text="A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography." /><sentence text="3'-Azido-3'-deoxythymidine (AZT) is the first clinically effective drug for the treatment of human immunodeficiency virus infection"><entity charOffset="0-26" id="DDI-PubMed.18258455.s2.e0" text="3'-Azido-3'-deoxythymidine" /><entity charOffset="28-31" id="DDI-PubMed.18258455.s2.e1" text="AZT" /><pair ddi="false" e1="DDI-PubMed.18258455.s2.e0" e2="DDI-PubMed.18258455.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18258455.s2.e0" e2="DDI-PubMed.18258455.s2.e1" /></sentence><sentence text=" The drug interaction with human serum albumin (HSA) has been an important component in understanding its mechanism of action, especially in drug distribution and in drug-drug interaction on HSA in the case of multi-drug therapy" /><sentence text=" We present here crystal structures of a ternary HSA-Myr-AZT complex and a quaternary HSA-Myr-AZT-SAL complex (Myr, myristate; SAL, salicylic acid)"><entity charOffset="132-146" id="DDI-PubMed.18258455.s4.e0" text="salicylic acid" /><entity charOffset="57-70" id="DDI-PubMed.18258455.s4.e1" text="AZT" /><entity charOffset="94-107" id="DDI-PubMed.18258455.s4.e2" text="AZT" /><pair ddi="false" e1="DDI-PubMed.18258455.s4.e1" e2="DDI-PubMed.18258455.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18258455.s4.e1" e2="DDI-PubMed.18258455.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18258455.s4.e1" e2="DDI-PubMed.18258455.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18258455.s4.e2" e2="DDI-PubMed.18258455.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18258455.s4.e2" e2="DDI-PubMed.18258455.s4.e0" /></sentence><sentence text=" From this study, a new drug binding subsite on HSA Sudlow site 1 was identified" /><sentence text=" The presence of fatty acid is needed for the creation of this subsite due to fatty acid induced conformational changes of HSA"><entity charOffset="17-27" id="DDI-PubMed.18258455.s6.e0" text="fatty acid" /><entity charOffset="78-88" id="DDI-PubMed.18258455.s6.e1" text="fatty acid" /><pair ddi="false" e1="DDI-PubMed.18258455.s6.e0" e2="DDI-PubMed.18258455.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18258455.s6.e0" e2="DDI-PubMed.18258455.s6.e1" /></sentence><sentence text=" Thus, the Sudlow site 1 of HSA can be divided into three non-overlapped subsites: a SAL subsite, an indomethacin subsite and an AZT subsite"><entity charOffset="129-138" id="DDI-PubMed.18258455.s7.e0" text="AZT" /></sentence><sentence text=" Binding of a drug to HSA often influences simultaneous binding of other drugs" /><sentence text=" From the HSA-Myr-AZT-SAL complex structure, we observed the coexistence of two drugs (AZT and SAL) in Sudlow site 1 and the competition between these two drugs in subdomain IB"><entity charOffset="10-25" id="DDI-PubMed.18258455.s9.e0" text="HSA-Myr-AZT-SAL" /><entity charOffset="18-32" id="DDI-PubMed.18258455.s9.e1" text="AZT" /><entity charOffset="87-101" id="DDI-PubMed.18258455.s9.e2" text="AZT" /><pair ddi="false" e1="DDI-PubMed.18258455.s9.e0" e2="DDI-PubMed.18258455.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18258455.s9.e0" e2="DDI-PubMed.18258455.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18258455.s9.e0" e2="DDI-PubMed.18258455.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18258455.s9.e1" e2="DDI-PubMed.18258455.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18258455.s9.e1" e2="DDI-PubMed.18258455.s9.e2" /></sentence><sentence text=" These results provide new structural information on HSA-drug interaction and drug-drug interaction on HSA" /><sentence text="" /></document>